GAGargee Anand

Gargee Anand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gargee Anand has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Device-Associated Sepsis and Brain Injury: Transitioning From Early Infection Control to Late Neuroprotection

    by Gargee Anand, Rijhul Lahariya

    Summary Sepsis-associated encephalopathy (SAE) is a complex neuroinflammatory condition characterized by diffuse brain dysfunction arising from systemic infection without direct central nervous system invasion. In modern critical care, device-associated infections (DAIs) caused by invasive medical devices, such as central line-associated bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections, have become critical drivers of intensive care unit (ICU)-acquired sepsis. Biofilm formation on these devices establishes persistent inflammatory reservoirs that continuously shed microorganisms, pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs) into the circulation, sustaining systemic immune activation. This review outlines an integrated mechanistic framework linking DAIs to acute brain dysfunction. Systemic inflammation and endothelial activation trigger microvascular dysfunction, impaired cerebral autoregulation, and blood–brain barrier disruption. These peripheral vascular alterations allow inflammatory mediators to access the central nervous system, where they induce microglial and astrocytic reactivity. Persistent neuroimmune activation compromises neurotransmitter homeostasis—causing glutamate excitotoxicity and cholinergic deficits—while impairing neuronal mitochondrial oxidative phosphorylation. The resulting oxidative stress, energy failure, and self-amplifying neuroinflammatory feedback loops culminate in synaptic damage and neuronal injury. Clinically, this manifests as altered consciousness, delirium, seizures, and long-term neurocognitive impairment. By framing SAE as a concurrent, multidimensional continuum rather than a linear sequence, this review highlights the critical role of early infection prevention, timely device removal, and targeted neuroprotective strategies aimed at stabilizing vascular integrity and mitigating neuroinflammation.

  • Top Cited Papers

    Time-dependent neurovascular unit dysfunction in ischemic stroke: mechanisms of neurovascular uncoupling and its clinical impact

    by Rijhul Lahariya, Mainak Sinha, Bandana Kumari, Keyush Venket Subramanian, Gargee Anand

    Neurovascular unit (NVU) dysfunction is a central determinant of tissue injury, reperfusion failure, and long-term neurological outcomes after ischemic stroke. This review critically examines the cellular and molecular mechanisms underlying NVU disruption, with a particular focus on inflammation, oxidative stress, and blood-brain barrier (BBB) integrity, and evaluates emerging NVU-targeted therapeutic strategies. A focused narrative review synthesized studies on ischemic stroke-related NVU alterations, integrating cellular mechanisms, biomarkers, and phase-specific therapeutic strategies targeting BBB dysfunction, inflammation, oxidative stress, and neurorestoration. Acute ischemic injury induces endothelial tight-junction disruption, pericyte constriction and loss, astrocytic activation, and microglial-driven inflammation, resulting in BBB breakdown, impaired neurovascular coupling, and restricted microvascular reperfusion. These processes facilitate leukocyte infiltration, exacerbate secondary neuronal damage, and increase hemorrhagic transformation risk. Circulating and cerebrospinal fluid biomarkers, including MMP-9, GFAP, S100B, and pro-inflammatory cytokines, reflect NVU injury severity and correlate with functional outcomes. In the chronic phase, persistent BBB permeability, maladaptive VEGF signaling, and sustained low-grade inflammation contribute to white matter injury, impaired neuroplasticity, and post-stroke cognitive decline. Therapeutic strategies targeting NVU dysfunction include anti-inflammatory agents, COX-2 inhibitors, and NADPH oxidase inhibitors, alongside stem cell-based and extracellular vesicle-mediated approaches that promote vascular stabilization and repair. Neuroplasticity-enhancing interventions and nanoparticle-based drug delivery systems further support functional recovery. NVU dysfunction underlies both acute injury amplification and chronic recovery failure after stroke. Biomarker-guided, phase-specific therapeutic strategies targeting inflammation, oxidative stress, and BBB instability represent a promising framework for personalized stroke management.


  • Open Access

    Early detection of central line-associated bloodstream infection in intensive care unit patients using the systemic inflammatory response index (SIRI)

    by Rijhul Lahariya, Gargee Anand

    Central line-associated bloodstream infections (CLABSIs) are life-threatening complications in critically ill patients, necessitating early identification for timely intervention. This study evaluates the predictive performance of Systemic Inflammatory Response Index (SIRI), a novel composite marker derived from routine blood counts, for early prediction of CLABSI within first two calendar days following central venous catheter (CVC) insertion. In this observational study at a tertiary ICU, 234 adults with CVCs for over two days were classified as CLABSI-positive or negative per CDC/NHSN criteria. SIRI was calculated using the formula (neutrophils×monocytes/lymphocytes) based on day 2 complete blood counts. Logistic regression and receiver operating characteristic (ROC) curve analysis was done to determine diagnostic performance. CLABSI was diagnosed in 39 patients. Median SIRI values were significantly higher in CLABSI group (37.3 vs. 12.0; p<0.001). In univariate logistic regression, SIRI emerged as an independent predictor of CLABSI (OR=1.0097; 95% CI: 1.001–1.018; p=0.015). ROC analysis demonstrated a moderate discriminative power with AUROC=0.72 (95% CI: 0.64–0.80). At optimal threshold, SIRI achieved 84.6% sensitivity, 52.8% specificity, 58.1% accuracy, 26.4% positive predictive value (PPV) and a notably high negative predictive value (NPV) of 94.5%, supporting its value as an early rule-out marker for CLABSI. SIRI, derived from routine complete blood counts, shows strong potential as a non-invasive, early screening marker for CLABSI. Its high sensitivity and NPV support its use for early rule-out, especially in settings lacking rapid diagnostics. Further prospective validation is warranted.


  • Open Access

    Healthcare-associated infections

    by Gargee Anand, Rijhul Lahariya

    Healthcare-associated infections (HAIs) continue to be a leading cause of morbidity, mortality, and increased healthcare costs worldwide. Despite advances in infection prevention, the burden of HAIs remains high, exacerbated by the rise of antimicrobial resistance (AMR) and the growing complexity of patient care. Effective prevention strategies are critical to reducing HAI rates and improving patient outcomes. This review aims to highlight the clinical significance of HAIs, explore their impact on patient safety, and underscore the necessity for robust surveillance and infection control (IC) programs across healthcare settings. The study found that HAIs continue to affect a significant proportion of hospitalized patients, with invasive devices and antimicrobial-resistant pathogens being key contributors. Surveillance systems, when combined with targeted IC protocols and continuous staff education, can reduce HAI incidence and improve patient safety. Moreover, the implementation of antimicrobial stewardship programs and proper hygiene practices along with emerging technologies plays a pivotal role in curbing the spread of resistant organisms. Healthcare systems must prioritize HAI prevention to safeguard patient safety, reduce treatment costs, and combat the growing threat of AMR.


  • Bloodstream Infection-induced Neuroinflammation: from Systemic Infection To Brain Invasion

    by Gargee Anand, Rijhul Lahariya

    Bloodstream infections (BSIs), caused by a diverse array of microbial pathogens, have emerged as key drivers of systemic inflammation that can compromise the integrity of blood-brain barrier (BBB) and trigger neuroinflammatory responses. This review highlights the pivotal role of BSIs in initiating neuroinflammation and accelerating the progression of neurodegenerative diseases (NDDs). Literature review shows that pathogens involved in BSIs can disrupt the BBB, activate neuroglial cells, and release pro-inflammatory cytokines, ultimately causing neuronal injury and fueling chronic neuroinflammation. Clinically, survivors of BSIs, especially those who experience sepsis, face a heightened risk of long-term neurological decline. While antimicrobial treatments remain essential, advanced therapeutic options such as psychedelics, immunomodulators, and nano pharmacology, gene therapies offer promising strategies to mitigate neuroinflammation and protect brain function. The review emphasizes the urgency of early intervention, particularly in sepsis patients, to prevent the onset of chronic NDDs and preserve cognitive health. A deeper understanding of the mechanisms underlying BSI-induced neuroinflammation will be critical in developing personalized treatments to reduce the neurological burden associated with these infections. Ultimately, this review aims to provide clinicians with insights into neuroprotective strategies that have shown promise in animal models of BSIs, with the potential to improve patient outcomes if validated in humans; further clinical studies are essential to translate these findings into effective therapies for long-term neurological consequences.


  • Trained Immunity in sepsis: Exploring the molecular link to long-term cardiometabolic disorders

    by Rijhul Lahariya, Gargee Anand, Bandana Kumari

    Sepsis, a life-threatening systemic infection, has long been recognized for its immediate risks, but its long-term consequences on health are increasingly evident, particularly in predisposing survivors to chronic cardiometabolic disorders (CMDs) such as atherosclerosis, insulin resistance, and dyslipidemia. Central to this process is trained immunity, where innate immune cells like monocytes, macrophages, and neutrophils undergo long-lasting epigenetic reprogramming after sepsis. This reprogramming, sustained by molecular pathways such as NF-κB, mTOR, and altered lipid metabolism, drives chronic inflammation, oxidative stress, and metabolic dysfunction, contributing to long-term cardiovascular diseases (CVDs) and metabolic disorders post-sepsis. This review explores the key mechanisms through which trained immunity bridges sepsis and CMDs, particularly focusing on epigenetic modifications such as histone acetylation, DNA methylation, and mitochondrial alterations. We discuss how trained immunity enhances immune cell activation, leading to persistent low-grade inflammation, lipid dysregulation, and impaired insulin sensitivity, all of which predispose sepsis survivors to CVDs. Additionally, we highlight potential therapeutic approaches targeting trained immunity, including statins, which reduce inflammation and immune reprogramming; metformin, which restores metabolic balance by activating AMPK and reducing oxidative stress; dimethyl fumarate (DMF), a potent Nrf2 activator that counteracts inflammation; and probiotics, which help restore gut microbiota balance and limit endotoxin-driven inflammation. These therapies offer promising strategies to mitigate long-term metabolic dysfunction and reduce the incidence of CMDs following sepsis. Understanding these mechanisms and developing targeted interventions may ultimately help prevent chronic cardiovascular and metabolic diseases in sepsis survivors and improve long-term outcomes.


  • Emerging threat of WHO priority pathogens in ICU-associated CLABSI and CAUTI: an integrated analysis of resistance patterns, epidemiological trends, and stewardship strategies

    by Gargee Anand, Rijhul Lahariya, Ketan Priyadarshi, Asim Sarfraz

    To unmask the alarming prevalence, intricate antimicrobial resistance patterns, and consequential clinical outcomes of World Health Organization (WHO) priority pathogens causing device-associated infections in critical care settings - a frontier analysis of silent pandemic threatening modern healthcare. This groundbreaking retrospective study analysed data from 5,398 patients at risk for central line-associated bloodstream infections (CLABSI) and 15,416 patients for catheter-associated urinary tract infections (CAUTI) spanning 2021-2024. Microbial isolates were categorized according to WHO's priority pathogen classifications. Antimicrobial susceptibility profiles were comprehensively analysed using Clinical and Laboratory Standards Institute guidelines, with statistical analyses elucidating pathogen distribution dynamics, resistance mechanisms, and mortality correlations. Striking findings revealed WHO priority pathogens dominated the microbial landscape, constituting 76.47% of CLABSI and 82.14% of CAUTI isolates - with critical priority organisms overwhelmingly predominant (83.34% and 91.3%, respectively). Carbapenem-resistant Enterobacterales (CRE) emerged as the formidable leading threat (39.5% of CLABSI, 72.7% of CAUTI), while Carbapenem-resistant Acinetobacter baumannii (CRAB) demonstrated exceptional virulence with devastating mortality (93.33%). The study unveiled unprecedented levels of multidrug resistance, with most therapeutic options rendered ineffective; only colistin maintained universal efficacy against gram-negative isolates despite its concerning toxicity profile. Dramatic disparities in infection outcomes revealed CLABSI-associated mortality rates (71.79%) significantly eclipsed CAUTI (39.13%), establishing infection type as a critical independent predictor of survival. This landmark investigation exposes the crossroad between WHO priority pathogens and healthcare-associated infections, sounding an urgent alarm for global healthcare systems. Our findings provide crucial evidence-based guidance for recalibrating therapeutic approaches, optimizing antimicrobial selection, and prioritizing infection control measures in intensive care settings worldwide.